Non-HLA barriers to unrelated donor stem cell transplantation

Bone Marrow Transplantation
C KollmanDennis L Confer

Abstract

A prospective survey involving 544 searches of the US National Marrow Donor Program (NMDP) Registry was conducted to identify reasons why many patients who have apparent HLA-matched donors do not proceed to transplant. Coordinators at NMDP transplant centers, patients and referring physicians were surveyed shortly after the initial search, and follow-up surveys were sent to the coordinators as the search was ongoing. The death of the patient, worsening of the patient's medical condition and length of the search process were the most commonly cited barriers to transplantation. Other times a decision was made not to transplant through the NMDP due to the use of a donor from another source, a preference for chemotherapy or immunotherapy, hesitancy on the part of the transplant physician or patient, or because the patient did not require a transplant. Responses differed between U.S. and international cases. An unrelated donor outside the NMDP was the most common reason cited by international coordinators (46%), whereas the death of the patient was the most common reason among US coordinators (13%). The death of the patient was the second most common reason cited by international coordinators at 9%. Financial problems were listed by...Continue Reading

References

Sep 4, 1980·The New England Journal of Medicine·J A HansenE R Giblett
Feb 1, 1994·Seminars in Oncology Nursing·K Welte
Mar 4, 1993·The New England Journal of Medicine·N A KernanJ McCullough
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·E W PetersdorfJ A Hansen
Aug 24, 1999·Bone Marrow Transplantation·G E SwitzerR G Simmons

❮ Previous
Next ❯

Citations

Nov 8, 2011·Bone Marrow Transplantation·N S MajhailE M Denzen
Jan 7, 2006·Leukemia & Lymphoma·David I Marks
Feb 8, 2014·Cytotherapy·Salyka Sengsayadeth, Bipin N Savani
Jul 3, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Song YaoPhilip L McCarthy
Jan 25, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Akiko M SaitoStephanie J Lee
Dec 29, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailJ Douglas Rizzo
Sep 29, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·James L GajewskiRichard T Maziarz
Feb 10, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Elizabeth A MurphyNavneet S Mahjail
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franco AversaMassimo F Martelli
Jan 11, 2005·Bone Marrow Transplantation·S M van WalravenM Oudshoorn
Nov 5, 2002·Nature Reviews. Immunology·J Andrew BradleyRoger A Pedersen
Jul 17, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Edward W LiWarren Fingrut

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.